SEC Form 4 · accession 0001140361-18-029511
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David C Hastings
Officer — Chief Financial Officer
Period of report
Jun 19, 2018
Accepted (ET)
Jun 21, 2018 · 5:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $6.75 | Jun 19, 2018 | A | 200,000 | A | — | Jun 19, 2028 | Common Shares | 200,000 | 200,000 | D |
Explanation of responses
- F1The options vest as follows: 1/3 on 6/11/2019; 1/3 on 6/11/2020; and 1/3 on 6/11/2021.